BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24534946)

  • 1. Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors.
    Zitzmann F; Mayr D; Berger M; Stehr M; von Schweinitz D; Kappler R; Hubertus J
    Oncol Rep; 2014 Apr; 31(4):1871-6. PubMed ID: 24534946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.
    Hancock AL; Brown KW; Moorwood K; Moon H; Holmgren C; Mardikar SH; Dallosso AR; Klenova E; Loukinov D; Ohlsson R; Lobanenkov VV; Malik K
    Hum Mol Genet; 2007 Feb; 16(3):343-54. PubMed ID: 17210670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor.
    Satoh Y; Nakagawachi T; Nakadate H; Kaneko Y; Masaki Z; Mukai T; Soejima H
    J Biochem; 2003 Mar; 133(3):303-8. PubMed ID: 12761165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective methylation of CpGs at regulatory binding sites controls NNAT expression in Wilms tumors.
    Hubertus J; Zitzmann F; Trippel F; Müller-Höcker J; Stehr M; von Schweinitz D; Kappler R
    PLoS One; 2013; 8(6):e67605. PubMed ID: 23825673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
    Roberts DJ; Haber D; Sklar J; Crum CP
    Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
    Werner H; Roberts CT; Rauscher FJ; LeRoith D
    J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
    Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
    Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms' tumor-specific methylation pattern in 11p13 detected by PFGE.
    Royer-Pokora B; Schneider S
    Genes Chromosomes Cancer; 1992 Sep; 5(2):132-40. PubMed ID: 1381949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms' tumor protein (-KTS) modulates renin gene transcription.
    Steege A; Fähling M; Paliege A; Bondke A; Kirschner KM; Martinka P; Kaps C; Patzak A; Persson PB; Thiele BJ; Scholz H; Mrowka R
    Kidney Int; 2008 Aug; 74(4):458-66. PubMed ID: 18496514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
    Ramani P; Cowell JK
    J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of WTAP, a novel Wilms' tumour 1-associating protein.
    Little NA; Hastie ND; Davies RC
    Hum Mol Genet; 2000 Sep; 9(15):2231-9. PubMed ID: 11001926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
    Gashler AL; Bonthron DT; Madden SL; Rauscher FJ; Collins T; Sukhatme VP
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10984-8. PubMed ID: 1332065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
    Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
    Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target.
    Shahidul Makki M; Cristy Ruteshouser E; Huff V
    Exp Cell Res; 2013 Mar; 319(5):612-22. PubMed ID: 23291318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site.
    Cui H; Niemitz EL; Ravenel JD; Onyango P; Brandenburg SA; Lobanenkov VV; Feinberg AP
    Cancer Res; 2001 Jul; 61(13):4947-50. PubMed ID: 11431321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor.
    Malik K; Salpekar A; Hancock A; Moorwood K; Jackson S; Charles A; Brown KW
    Cancer Res; 2000 May; 60(9):2356-60. PubMed ID: 10811108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor and the WT1 gene.
    Hata J
    Contrib Nephrol; 1999; 128():62-74. PubMed ID: 10597378
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
    Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
    Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.